Geriatric Psychiatry Update: ChEIs for Psychotic Symptoms
According to this recent meta-analysis published in JAMA Neurology on June 26, 2023: Cholinesterase Inhibitors treatment improves psychotic symptoms in patients with Alzheimer’s disease &…
Tag: Alzheimer’s Disease
Apathy in Alzheimer’s Disease: Basics & Beyond
PSYCHIATRY EDUCATION FORUM ACADEMY’S APATHY IN ALZHEIMER’S DISEASE BASICS & BEYOND Alzheimer’s disease, a progressive neurodegenerative disorder, not only affects memory and cognitive functions but…
Lecanemab: FDA Approved for Early Alzheimer’s Disease
On July 06, 2023: FDA announced the approval of Leqembi (Lecanemab) for adult patients with early Alzheimer’s Disease or mild cognitive impairment. Psychiatry Education Forum…
First FDA Approved Medication for Agitation Associated with Alzheimer’s Dementia
On May 11, 2023: FDA announced the approval of Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the…
First Weekly Transdermal Patch Approved for Alzheimer’s Dementia: ADLARITY
On March 14, 2022: FDA has approved the first and only once-weekly transdermal patch for Alzheimer’s dementia: Adlarity (Donepezil). Psychiatry Education Forum Academy has summarized…
How to Evaluate Six Neurocognitive Domains in Dementia? [PUBLISHED]
Psychiatry Education Forum Academy published its next discussion series today: It is important to have knowledge of these six neuro-cognitive domains for the evaluation &…
Alzheimer’s Disease: Comparing FDA Approved Medications
Alzheimer’s disease is the most common type/cause of dementia. As we know that FDA recently approved Aducanumab (Aduhelm) for the treatment of Alzheimer’s Disease (read…
Aducanumab: New Medication FDA Approved for Alzheimer’s Disease
June 07, 2021 Today FDA has approved Aducanumab (Aduhelm) for the treatment of Alzheimer’s Disease. This is the first novel treatment to target the underlying…